<SEC-DOCUMENT>0001206774-14-000844.txt : 20140312
<SEC-HEADER>0001206774-14-000844.hdr.sgml : 20140312
<ACCEPTANCE-DATETIME>20140312160017
ACCESSION NUMBER:		0001206774-14-000844
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140311
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140312
DATE AS OF CHANGE:		20140312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		14687493

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>geroncorp_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor="#ffffff">
<BR>
<P align=center><B><FONT face="Times New Roman" size=2>UNITED
STATES<BR></FONT></B><B><FONT face="Times New Roman" size=2>SECURITIES AND
EXCHANGE COMMISSION <BR>WASHINGTON, D.C. 20549
<BR>___________<BR></FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>FORM 8-K </FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>CURRENT
REPORT<BR></FONT></B><B><FONT face="Times New Roman" size=2>PURSUANT TO SECTION
13 OR 15(d) OF THE <BR>SECURITIES EXCHANGE ACT OF 1934</FONT></B><FONT face="Times New Roman" size=2> </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>Date of Report (Date of
earliest event reported): </FONT><B><FONT face="Times New Roman" size=2>March
11, 2014</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>GERON
CORPORATION</FONT></B><FONT face="Times New Roman" size=2> <BR></FONT><FONT face="Times New Roman" size=2>(Exact name of registrant as specified in its
charter) </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><B><FONT face="Times New Roman" size=2>Delaware</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><B><FONT face="Times New Roman" size=2>0-20859</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><B><FONT face="Times New Roman" size=2>75-2287752</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>(State or other jurisdiction</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>(Commission File Number)</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>(IRS Employer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>of incorporation)</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>Identification
No.)</FONT></TD></TR></TABLE><BR>
<P align=center><B><FONT face="Times New Roman" size=2>149 COMMONWEALTH DRIVE,
SUITE 2070 <BR>MENLO PARK, CALIFORNIA 94025 <BR></FONT></B><FONT face="Times New Roman" size=2>(Address of principal executive offices, including
zip code) </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>(650)
473-7700<BR></FONT></B><FONT face="Times New Roman" size=2>(Registrant&#146;s
telephone number, including area code) </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>N/A <BR></FONT></B><FONT face="Times New Roman" size=2>(Former name or former address, if changed since
last report) </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions: </FONT></P>
<TABLE style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face=Wingdings>o</FONT></TD>
    <TD vAlign=top align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD vAlign=top align=left width="97%"><FONT face="Times New Roman" size=2>Written communications pursuant to Rule 425 under the Securities
      Act (17 CFR 230.425)</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="97%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face=Wingdings>o</FONT></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="97%"><FONT face="Times New Roman" size=2>Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="97%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face=Wingdings>o</FONT></TD>
    <TD vAlign=top align=left width="1%">&nbsp;</TD>
    <TD vAlign=top align=left width="97%"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="97%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face=Wingdings>o</FONT></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="97%"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=LEFT><B><FONT face="Times New Roman" size=2>Item 8.01. Other Events.
</FONT></B></P>
<P align=LEFT><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>On March 12, 2014, Geron Corporation
issued a press release entitled &#147;Geron Announces IND Clinical Hold Affecting
Clinical Trials of Imetelstat in Essential Thrombocythemia and Multiple
Myeloma.&#148; A copy of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by reference.</FONT></P>
<P align=LEFT><B><FONT face="Times New Roman" size=2>Item 9.01. Financial Statements and
Exhibits.</FONT></B></P>
<P align=LEFT><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>(d) Exhibits. </FONT></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=2>Exhibit
No.</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%"><B><FONT face="Times New Roman" size=2>Description</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" noWrap width="1%"></TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>99.1</FONT></TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" width="96%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Press release, dated
      March 12, 2014, entitled &#147;Geron Announces IND Clinical Hold Affecting
      Clinical Trials of Imetelstat in Essential Thrombocythemia and Multiple
      Myeloma.&#148;</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>1</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>SIGNATURE</FONT></B></P>
<P align=LEFT><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.</FONT></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2><P align=LEFT><FONT face="Times New Roman" size=2>GERON
      CORPORATION</FONT></P></TD></TR>
  <TR>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%">
      <P align=LEFT><FONT face="Times New Roman" size=2>Date: March 12,
2014</FONT></P></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>By:</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="49%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;/s/ Stephen N. Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>Stephen N. Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>Executive Vice President,
  General</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>Counsel and Corporate
  Secretary</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>2</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>EXHIBIT</FONT></B><B><FONT face="Times New Roman" size=2> </FONT></B><B><FONT face="Times New Roman" size=2>INDEX</FONT></B></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><FONT size=+0><B><FONT face="Times New Roman" size=2>Exhibit
      No.</FONT></B></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="98%"><FONT size=+0><B><FONT face="Times New Roman" size=2>Description</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>99.1</FONT></TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" width="98%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Press release, dated
      March 12, 2014, entitled &#147;Geron Announces IND Clinical Hold Affecting
      Clinical Trials of Imetelstat in Essential Thrombocythemia and Multiple
      Myeloma.&#148;</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>3</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99_1.htm
<DESCRIPTION>PRESS RELEASE, DATED MARCH 12, 2014
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>
<P align=right><B><FONT face="Times New Roman" size=2>EXHIBIT 99.1</FONT></B></P>

<IMG src="exhibit99_1x1x1.jpg" border=0><BR>
<P align=center><B><FONT face="Times New Roman" size=2>Geron Announces IND Clinical Hold
Affecting Clinical Trials of Imetelstat in Essential<BR>Thrombocythemia and
Multiple Myeloma</FONT></B></P>
<P align=center><I><FONT face="Times New Roman" size=2>Conference Call Today, March 12, at
8:30 a.m. EDT</FONT></I></P>
<P align=left><B><FONT face="Times New Roman" size=2>Menlo Park, Calif., March 12, 2014
&#150;&nbsp;</FONT></B><FONT face="Times New Roman" size=2>Geron Corporation (Nasdaq: GERN)
announced today that the company has received verbal notice from the U.S. Food
and Drug Administration (FDA) that its Investigational New Drug (IND)
application for imetelstat has been placed on full clinical hold, affecting all
ongoing company-sponsored clinical trials. A full clinical hold is an order that
the FDA issues to a trial sponsor to suspend an ongoing clinical trial or delay
a proposed trial.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>The clinical hold affects the remaining
eight patients in the company&#146;s Phase 2 study in essential thrombocythemia (ET) or
polycythemia vera (PV) and the remaining two patients in the company&#146;s Phase 2
study in multiple myeloma. In addition, the company&#146;s planned Phase 2 clinical
trial in myelofibrosis will likely be delayed due to the clinical hold. It is
possible that other studies using imetelstat, such as ongoing
investigator-sponsored trials, may also be placed on clinical hold by the
FDA.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Geron has not yet received written notice
of its clinical hold from the FDA, but based on the verbal communication
yesterday afternoon, the FDA indicated that the clinical hold is due to the
occurrence of persistent low-grade liver function test (LFT) abnormalities
observed in the Phase 2 study of imetelstat in ET/PV patients and the potential
risk of chronic liver injury following long-term exposure to imetelstat. The FDA
expressed concern about whether these LFT abnormalities are reversible. Geron
plans to work diligently with the FDA to seek the release of the clinical
hold.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Conference Call</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>This afternoon&#146;s previously scheduled
conference call to discuss the fourth quarter and annual 2013 financial results
is cancelled. These results will be reported in the company&#146;s Annual Report on
Form 10-K.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Geron&#146;s management will host a conference
call at 8:30 a.m. EDT to discuss the clinical hold. Participants can access the
conference call live via telephone by dialing 866-700-6293 (U.S.); 617-213-8835
(international). The passcode is 52642998. A live audio-only webcast is also
available at http://www.media-server.com/m/p/4rmnjn2s. The audio webcast of the
conference call will be available for replay approximately one hour following
the live broadcast through April 12, 2014.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>About Geron</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Geron is a clinical stage
biopharmaceutical company developing a first-in-class telomerase inhibitor,
imetelstat, in hematologic myeloid malignancies. For more information about
Geron, visit www.geron.com.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2>CONTACT:</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2>Anna Krassowska, Ph.D.<BR>Investor and
Media
Relations<BR>650-473-7765<BR>investor@geron.com<BR>media@geron.com</FONT><FONT face="Times New Roman" size=2> </FONT></P>

<P align=center><FONT face="Times New Roman" size=2>###</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exhibit99_1x1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit99_1x1x1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``Z`&@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^ZGXQ?&OX
M0_L]?#W7OBQ\=/B9X'^$7PT\,0I-KWCGXA^)=*\*>&M-$K;+:";5=8NK6V>]
MO9L6VG:?"\M_J5V\=I86UQ<RQQ-^9OP:_P""^_\`P1Z^/GQ&T[X4?#3]NSX4
MW?CC6+Q--T;3_%^D?$7X6Z3K&I33I:VNF:1XM^*7@KP9X0U34[^YDCM]-T^P
MUVXO-3FD2+3X+EW53^'_`/P=S6VL_%?Q[_P1N_9"U#Q-K&C?";]I?]K/Q=I7
MQ$T_29DB>[OK#Q!\`/AUX>UM0Z/')?\`AS0_C/X[.EB8/;I<:JTLD4C)&4P?
M^#A'_@AM_P`$U?V;O^"3OQ7^.G[-G[./ASX)?%7]G:Z^%NH^&?&7A76/%EUJ
M_B72=?\`B1X2\`:]H?CF?7?$&J#Q4FH:=XHEU./5M66YUJRUC3K*:TOXK22^
ML[L`_M?KXD_:_P#^"D'[#/[!%EI-W^UU^TO\-_@M=:]`]WH7AO6[S4M<\<ZW
M8QR/%)J6D?#WP?IOB+QUJ>E13(UO+JEEX=GT^.X'V=[E9L1GY5_X("_&'X@_
M'C_@CY^PS\2?BEXCU+Q=XXOOACKOAC5/$NL74M]J^KV7P[^)'C;X=^'KG5+Z
M<M<W^HKX:\*Z1!>ZA=237=_<Q2WEW--<SRR-_,3^SQ^Q]\%_^"LW_!S3_P`%
M/X/VX]'O_C!X$_9;BUF#X?\`PTO=7U'2_"5[;_#[Q=X*^%?@?1]?ATFYLKV[
M\,:+HTFIZU<^';6[L[+7/$U_)J&MF_MIM3L=2`/[`/V.?^"I/_!/[]O^^US1
M_P!D3]J#X?\`QA\1>&[-=2UGPA:0^)?!_CFSTII!$=8'@;XA:#X2\7W6BQ3-
M'!<ZQ9Z)<:9:W$T%O<W<4UQ"DGWW7^>A_P`%H?V._@%_P1Y_X*L?\$B_VCO^
M"?/@B']G[6?B_P#%S5+'QOX,\,ZKKESX)O/^$9\=_";PGK`T[1]7U/41HFG>
M-_!7Q6U_PKXHT+29+30KBQCBGM=-M;V>^N+K^T+_`(*?_'GQ]^R]_P`$\/VS
M?V@_A7>6VF_$KX2_L\?$OQAX#U6\LK74K;2/%NG^'KM=!UB73KV*>RU`:1J4
MMOJ0L;R&:TNVM5M[F-X))%(!H_'[_@I1_P`$_OV6=>F\)?M"_MD?LY_";QA:
ME1=^"_%OQ6\)6GC6RWA&1KWP?!J5QXELD=9$=)+K2X8V0[U8J"1[+H_[4'[.
M^N_`"#]JO3OC/\/&_9ON/"=QX[C^-EYXET_2_AR/!]K+-!/XBF\2ZI+9Z?;:
M7'/;RV_VBXEB#W"B!`TKHC?PQ_\`!O3_`,$&?V6O^"B'[-/BG_@HA_P46M?%
MO[1_C3X_?%;XC3^%O#M]\2/'/ABS6+1/$>H:3XP\<^.=6\&:SX<\4>(O&WBO
MQS'X@NU$WB'^R[33;:TN9K2ZO]1F^Q?JM_P<9_!OP1^S3_P1L^`'[#G[/&GS
M?"WX"_$7]KS]F#]F:;PW::GK/B6;2OAG?^(?%OQ)BTV'6/%NIZWK]\]GXV\%
M^'-;CGU+5KJYD;3UM9+@VKM%0!^CWA+_`(.'O^"+OC;QW;?#G0_V^_A/#XCN
M[]=,M[KQ+H7Q.\%>#'NWD\I-WQ)\9^!-`^'45L[X5+Z7Q4EB^5*W)5E)_9/3
MM1T_5]/L=6TF^L]3TO4[.VU'3=2TZYAO=/U#3[V%+FSOK&\MGEM[NSN[>6.X
MMKFWDDAGAD26)WC=6/\`)C_P5$_X-XO^"5'P;_X)5?M-^(OA#^SA:>!?BC^S
M;^SO\0_BMX"^,EIXL\8WOQ'U3Q1\./"=YXF:7QQJEYKCZ;XOM/%!TF:QU?3=
M4TE])T]-1GN/#.GZ%-;V1MOL#_@UN^-OC[XW?\$;/V>+GXAZO-KNH_"_Q!\1
M_@OX?U*Z8R7A\#?#WQ++9^"M,N)6),B^'?#UW9>&[`DDII6D:?"2?+S0!^O/
M[4_[:W[*'[$G@NV^(/[5WQ[^'/P-\+ZA--;:-/XUUM+?5_$=U;JCW-IX4\+6
M$=]XI\67EK')'+=6GAO1=4N+6)TEGBCC8,?F;]D__@LU_P`$P_VW_'T?PK_9
MC_:_^'?Q"^)-S;W%SIO@74M+\<_#?Q3KT=HIDNE\,:+\4_"?@F^\4W%K"KW-
MQ:^'(=4NH+..6\EA2UBEF3^5C]NWX!^"_P#@IW_P=A^#_P!CC]JNY\0>*OV<
M_@]\"-!NM(^'NDZW>^'[;4-+TGX(-\;+W0IM1TJ2VU&PM/%'CWQ(\GBB_P!+
MN+/7-0T&SMM'MM4L1;V%S9<)_P`'0O\`P3+_`&._^"</P@_9*_;7_84^%%A^
MS%\9]!_:;\,>#3=_#75O$%EH=VVF>#_%?Q$\*>)H]"U#5=0TW2_%/A?Q%X!L
MI;76-&@T^XU.+4+K^VSJ4L%C+;`'^@Y17S?^QO\`%?Q)\>/V0_V5OCCXRCL(
MO%_QF_9O^!WQ7\5Q:5`;73(O$GQ$^&/A?Q?KL>FVS/(;>P35-8NELX"[F&W$
M<9=BN24`?RQ?\'1__)\O_!O-_P!GG^,/_5O_`+%-?J%_P<X_\H0OVVO^P9\&
M?_6@_A37Y>_\'1__`"?+_P`&\W_9Y_C#_P!6_P#L4U^H7_!SC_RA"_;:_P"P
M9\&?_6@_A30!K_\`!M)_RA#_`&$O^Q5^+/\`ZT%\6:_'S_@BJ0/^#EC_`(+J
M$D``_$<DDX``^/?A`DDG@`#DD]*_8/\`X-I/^4(?["7_`&*OQ9_]:"^+-?C?
M_P`$:+%=3_X.1_\`@O)IK2&%=0L_BE8M*JAFB6[^.GA.`R*I*AB@DW!2P!(P
M2,YH`\\_X.Q?$.@:_P#ME?\`!$0Z%KFCZT+7XW_$);HZ3J=EJ0MFE^*G[+)B
M6X-G/,(6D$<AC$FTOL?;G:V/Z4/^"Y/_`"B"_P""BG_9K'Q._P#30:_GN^&O
M_!EW\(/AQ\5?A]\4X/V]OB;J]WX`^(7A3Q_;:1<_`_PO;V^HW'A;Q)8>(X]-
MEND^(DTEM%>R6"VLERD,KQ+(95AD*A#_`$(_\%R?^407_!13_LUCXG?^F@T`
M?$W_``:F_P#*$O\`9H_['+X_?^KM\<5P_P#P=._\F8?L;_\`:4+]DW_TT?%>
MNX_X-3?^4)?[-'_8Y?'[_P!7;XXKA_\`@Z=_Y,P_8W_[2A?LF_\`IH^*]`'Z
MD?\`!8C_`)12?\%'/^S*_P!I#_U5/B>ORH_X-$O^4-/@'_LO/QX_]26SK]5_
M^"Q'_**3_@HY_P!F5_M(?^JI\3U^5'_!HE_RAI\`_P#9>?CQ_P"I+9T`?`GA
M_P#Y77_&'_9NL?\`ZQOX:KU/_@]<_P"4<?[-G_9Y_AK_`-4I\::\L\/_`/*Z
M_P",/^S=8_\`UC?PU7J?_!ZY_P`HX_V;/^SS_#7_`*I3XTT`?T@_\$R_^4;O
M_!/K_LR']E#_`-4/X"HH_P""9?\`RC=_X)]?]F0_LH?^J'\!44`?S/?\'>0\
M5_"C7/\`@D5^VG!X0U/Q7\-_V4_VK/%>K^.H].98,ZMJ^L_`WXC>$M"FOW26
M+37\3V/P0\8:?9WUQ"]M'>11)(?,DABF9_P7'_X+;?\`!,+]M#_@CK^TE\+_
M`-G_`/:J\(^*_B[\4_#7P?OO"_PFO-"\:Z%X[-U8?&'X;>*-;T74-/U?PU:6
M-IJN@Z3IFJ3:DO\`:4EDW]G7+V%[?0M;RS_V!_%#X4_#'XV^!M>^&7QB^'O@
MOXI_#KQ3:BS\1^!_B!X:T?Q=X5UJV5UECCU'0M=L[[3KHP3(EQ;226[2VMS'
M%<V[Q3Q1R+_'-_P<&?\`!'3_`()*?L:_\$M_VD?V@/@W^RS\//@[\<+?5?A?
MH7PN\5:=XT^)[70\4^)_BMX1@U72?#OAS5_'>H^&[BZN_!:>+)&T]=#F@L](
MM=1O;>"V6P$]N`?L)_P;2?\`*$/]A+_L5?BS_P"M!?%FOYZ_V0/VK_@K_P`$
MV?\`@Z"_X*DZ)^V1XLLO@MX>_::NO$-GX!^(OBZ5-*\!V%UXY\2>!?C'X&F\
M4Z_=&.TT+1/$_A:XDM;7Q'>2)HUEKD<.GZG=6:3O<6_]#G_!M=:7-G_P1&_8
M/BNH)+>23P;\3[N-)5*,UM>_'KXJW=I.`>3'<VLT-Q"W1XI$=<JP)^H/V]_^
M"1'[`/\`P4HL[:;]JGX#Z+XE\<Z9I@TC0/B_X5O+WP/\7-!T^.1Y;:P@\;>'
MI+6]UG2;*66>6QT#Q7#XA\.VDUU=3V^DQSW,TC@'\[__``5*_P""TGQ,^,W_
M``4R_P""<?[%/_!(?]KNT\4/XK^)<&A?M+WWP>@\#^/?A]X@M_%'CGP/]DT&
M?Q?JOAGQ+97+^!_`GAOXA^(/%=_X0U,6&D:/K8%]?G4;&YATO]]?^"Y/_*(+
M_@HI_P!FL?$[_P!-!J/_`()^_P#!%3_@G=_P32U&^\5?LS_!*.+XGZE:2:=>
M?&+XCZS>?$+XG1Z;,KI<:;HFO:T/L?A"PO(W,6IVW@S2O#R:Q$L4>K_;U@@$
M?Z'?&;X.?#7]H3X5>/?@C\8_"UMXW^%OQ/\`#6H^#_'GA&\O=5TVU\0^&]6B
M\G4=+N+_`$._TO5[6*ZB^1YM/U"SNE'^KG0\T`?@Y_P:F_\`*$O]FC_L<OC]
M_P"KM\<5Q7_!UO9ZQI?_``38^&/Q?L]&O=:\._LZ_MR_LQ?&CQ_%8[!/;>$-
M+OO%O@T3+)*1%$]YXI\:^&-%@>4B,7>K6X<@$FOWH_9E_9=^`W[''P>\/?`+
M]FKX>6'PL^$/A2\UV_\`#_@O3-5\1:U9Z;=^)=8O/$&N31:AXJUC7=:E-_K&
MH7EZZ7&I31Q/.T=ND,"I$O9_&'X._"W]H'X9>,_@S\:_`?AKXF_"SXA:/)H/
MC/P+XNTV'5=`U_2WFANHX;RTF&4GL[VVM-2TR_MG@U#2=5L[+5=,NK34;.UN
M8@#^<#_@JS_P7#_X)C?$G_@D/^TY>?"_]JSX9?$'QC^TM^S=X^^%_P`,?A'X
M=UZWN_B\WB[XG^$Y?#$>G>+?A]#YWB'P0?"/]OG5/%5QXJM-*L+6UTVX@LKV
M]O;W28+_`-=_X-6OA-XS^%/_``1D_9^;QKIDND3_`!,\7?%;XL^'+.X1XKE_
M!GB[QC>1>%]3EC<!A%KNFZ5'KNG/@)<:3J5A=1EHYT=I_`O_``:P?\$9/`GQ
M:D^*L7[._B?Q9;I?_P!I:7\+?'7Q3\:>)_A/H]T)3*B1^&KO4$U+7=/C;C^R
M/&&O>)-)EB'DW%C/#F,_T&^'O#V@>$=`T3PKX5T32?#7ACPUI.GZ#X=\.Z#I
M]II&AZ%H>D6D5AI6CZ/I5A%;V.FZ7IMC;P6=A86<$-K:6L,4$$4<4:J`#^*7
MP_\`\KK_`(P_[-UC_P#6-_#5>I_\'KG_`"CC_9L_[//\-?\`JE/C37]+4'[`
M'[(%M^V!=_M\P?!71X_VN[[01X8NOC0/$/C4ZQ-H(\)6_@4:<?#[>)CX+6,>
M$[2WT?S$\-+<>5&+CS?MK/<MI_M@?L,?LI?M\>`/#WPN_:Z^#^D_&?P%X4\7
M6_CSP_X=UC7O&'A^WTWQ;:Z/K&@6^LI=>"_$7AO4)IHM(U[5[);>ZO)[,I>O
M*UL9XX98@#D_^"9?_*-W_@GU_P!F0_LH?^J'\!45]6?#KX?^#_A-\/O`GPK^
M'FB0^&O`'PS\&^&/A_X&\.6]S?7EOH'@_P`&:)8^'/#.B07>IW5[J5U#I6BZ
M;96,5SJ%[=WTZ0++=W5Q.TDKE`$?Q+T+7_%'PY\?^&?"FK?V#XI\1>"?%6A>
M&M=-W>V`T77]7T*_T_1]6-_IR2ZA9?V=J-Q;7GVNPCDO;;R?.M4>=(U/\0/P
MI_X-5?V__C_\1/#,?_!6#_@IGXD^.OP&\$ZA9>(M,^'O@GXQ?'?XPZYK^L0W
M*17FEK??''1/#NB?#ZTO])DN[.[\3Z%IOB+7Y+>XEL;6VL#*-1@_NTHH`X3X
M7_##X??!7X=^"OA)\*/".B^`OAM\.O#>D^$/!'@WP[:+9:)X;\-Z):1V6F:5
MI]N"S+#;6\2*9)7EN+B0O<7,TUQ++*_=T44`%%%%`!1110`4444`%%%%`!11
%10!__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
